Combination Therapy with Single Inhaler Budesonide/Formoterol Compared with High Dose of Fluticasone Propionate Alone in Patients with Moderate Persistent Asthma

Bateman, Eric D.; Bantje, Theo A.; Gomes, Maria João Marques; Toumbis, Michael; Huber, Rudolf M.; Naya, Ian; Eliraz, A

doi:10.1007/bf03256655

Cited by 72 publications

(29 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bateman and colleagues 228 reported that patients treated with BUD/FF had a lower incidence of mild asthma exacerbations than patients treated with FP, occurring in 50 patients (29.8%) and 74 patients (42.0%), respectively. Mild exacerbations were defined as awakening due to asthma on two consecutive nights, morning PEF at least 20% below that at baseline on two consecutive days or the need to use at least four inhalations of reliever medication.…”

Section: Exacerbationsmentioning

confidence: 99%

“…228 It was a multi-centre study conducted in 37 centres across six countries, involving the recruitment of 373 patients. Only 344 patients were randomised.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…Bateman and colleagues 228 reported that AE profiles were similar between the two treatments (no data given on rate of AEs). Out of five serious AEs occurring during the trial, two were in the BUD/FF group and three in the FP group.…”

Section: Adverse Eventsmentioning

confidence: 99%

See 2 more Smart Citations

Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over

Shepherd¹,

Rogers²,

Anderson³

et al. 2008

Health Technol Assess

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) Programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as royal colleges and NHS trusts. These sugges...

show abstract

Section: Exacerbationsmentioning

confidence: 99%

“…228 It was a multi-centre study conducted in 37 centres across six countries, involving the recruitment of 373 patients. Only 344 patients were randomised.…”

Section: Study Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over

Shepherd¹,

Rogers²,

Anderson³

et al. 2008

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…Studies suggest that daily asthma control improves to a greater extent with the addition of a LABA than with a higher ICS dose alone in patients with mild to severe asthma (13)(14)(15)(16). Systematic reviews have found a 12-14% reduction in the risk of an exacerbation with traditional ICS/LABA maintenance therapy plus SABA for relief compared with a higher ICS dose plus SABA in patients with moderate to severe asthma (17,18).…”

Section: The Role Of Ics and Laba In Improving Asthma Controlmentioning

confidence: 99%

Budesonide/formoterol for maintenance and reliever therapy in the management of moderate to severe asthma

Humbert

Andersson

Buhl³

2008

Allergy

View full text Add to dashboard Cite

The Global Initiative for Asthma (GINA) guidelines aim at improving asthma control and preventing future risk. For patients with moderate to severe asthma an inhaled corticosteroid (ICS) or an ICS/long‐acting β2‐agonist (LABA) combination with a short‐acting β2‐agonist (SABA) as reliever is recommended. Despite the availability of effective maintenance therapies, a large proportion of patients still fail to achieve guideline‐defined asthma control, and overuse of SABA reliever medication at the expense of ICS is commonly observed. New simplified treatment approaches may offer a solution and assist physicians to achieve overall asthma control. One such treatment approach, which is recommended in the GINA guidelines, is budesonide/formoterol for both maintenance and reliever therapy. This treatment strategy significantly reduces the rate of severe asthma exacerbations compared with ICS/LABA plus SABA and achieves equivalent daily symptom control compared with higher doses of ICS/LABA plus separate SABA for relief. These benefits are achieved at a lower overall steroid load, and budesonide/formoterol maintenance and reliever therapy is well tolerated in patients with moderate to severe asthma. This review discusses current asthma management in patients with moderate to severe disease and examines the evidence for alternative asthma management approaches.

show abstract

“…[54]. Alternative strategies to lower the C o p y r ig h t G e n e r a l P r a c t ic e A ir w a y s G r o u p R e p r o d u c t io n p r o h ib it e d total daily dose of ICS include the addition of longacting bronchodilators or leukotriene modifiers in people with moderate to severe asthma, but not in those patients with mild persistent asthma [55][56][57][58]. Such new agents and new strategies would potentially reduce both the incidence and fear of adverse events due to ICS -an important consideration in achieving patient adherence.…”

Section: Systemic Corticosteroidsmentioning

confidence: 99%

Asthma management: Are GINA guidelines appropriate for daily clinical practice?

Yawn

Molen

Humbert

2005

Primary Care Respiratory Journal

View full text Add to dashboard Cite

SummaryAn international group of primary care asthma experts, as well as pulmonologists and allergists from Europe and the US, met to discuss asthma management focused on the primary care office. This paper summarizes their discussions. Accuracy of diagnosis and appropriateness of treatment is variable depending on the clinical circumstances and patient group. The value of classifying patients based on baseline or static asthma severity scores remains controversial, and asthma management decisions based on symptom control appear to have greater practical utility in a primary care setting. Furthermore, it must be recognized that patients, caregivers and physicians may have differing, and possibly conflicting, goals for therapy. There are many initiatives to improve the quality of asthma management, for example, primary care-focused guidelines being developed by the International Primary Care Respiratory Group, and several groups are working on asthma control scores. In addition, new therapies may improve the options available for increasing compliance and reducing side effects. In conclusion, asthma management should be patient-focused, with outcomes relevant to improving the quality of life for people with asthma.

show abstract

Combination Therapy with Single Inhaler Budesonide/Formoterol Compared with High Dose of Fluticasone Propionate Alone in Patients with Moderate Persistent Asthma

Abstract: Symbicort (budesonide/formoterol in a single inhaler) was more effective than a high dose of fluticasone propionate in improving lung function, reducing use of reliever medication and improving control of moderate persistent asthma.

Cited by 72 publications

References 15 publications

Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over

Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over

Budesonide/formoterol for maintenance and reliever therapy in the management of moderate to severe asthma

Asthma management: Are GINA guidelines appropriate for daily clinical practice?

Contact Info

Product

Resources

About